ClinicalTrials.gg
RecruitingNCT07321652Updated Nov 3, 2026

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

A Phase 3 interventional study of Zanubrutinib and Sonrotoclax in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia, sponsored by Alliance for Clinical Trials in Oncology. Recruiting at 261 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 3, 2026Site recruiting status changed51 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 11 under way, 4 of them phase 3. sonrotoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
4th of 11
466 · median 100
Started
2026
with 2 others
Phase 3
4 of 11
3 open now
Primary completion
2028-09
later than 4 of 10 live
Registered
9th of 11
by date
Lead sponsor
1 of 11
Alliance for Clinical Trials in Oncology

Among the 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 4 of the 10 other live ones, and was the 9th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sonrotoclax

sonrotoclax: first FDA approval 2026 (BEQALZI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing sonrotoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving sonrotoclax and zanubrutinib may be more effective than zanubrutinib alone for the treatment of untreated CLL/SLL.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare the progression free survival (PFS) between minimal residual disease (MRD)-guided zanubrutinib sonrotoclax therapy to continuous zanubrutinib as control.

II. To determine the PFS comparing fixed duration zanubrutinib sonrotoclax therapy to continuous zanubrutinib as control.

SECONDARY OBJECTIVES:

I. To compare the PFS between the patients with MRD-detectable disease treated with fixed duration zanubrutinib sonrotoclax to the PFS of the patients with MRD detectable disease who receive one additional year of combination therapy.

II. To determine the overall survival of all arms of the study. III. To determine the frequency of patients with MRD-detectable disease who convert to undetectable MRD, and at what depth and for how long, after receiving an extra year of combination therapy on the MRD-guided zanubrutinib sonrotoclax therapy arm.

IV. To determine and compare the overall response rate (ORR defined as PR, CR, CCR, CRi) and complete remission rate (CR) after 14 cycles of therapy among the three arms.

V. To compare time to the next CLL/SLL therapy among treatment arms. VI. To determine the rates and severity of toxicity in each arm, with a particular focus on adverse events of special interest that include infections, cardiovascular events (arrhythmias, heart failure, hypertension), tumor lysis syndrome, bleeding events, cytopenias, and second malignancies.

VII. To compare patient-reported symptomatic adverse events as assessed by the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE) between arms 1 and 2.

EXPLORATORY OBJECTIVES:

I. To compare the best achieved rate of undetectable MRD (uMRD) between the fixed duration zanubrutinib sonrotoclax arm and the MRD guided zanubrutinib sonrotoclax arm.

II. To compare rates of undetectable MRD measured by the immunoglobulin heavy chain (IGH) sequencing assay ClonoSeq (sensitivity 1 in 10\^-6) to undetectable MRD measured by standard six-color flow cytometry (uMRD4), and to compare results from bone marrow to peripheral blood.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive zanubrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with at least partial remission continue therapy as described above. Patients with progressive disease proceed to follow up. Patients undergo computed tomography (CT) scan, bone marrow aspiration and blood sample collection throughout the study.

ARM 2: Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Starting cycle 4 day 1 patients also receive sonrotoclax PO daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with undetectable MRD and a response of PR, partial response with persistent lymphocytosis (PR-L), CR, CCR or CRi stop therapy at cycle 15 day 28 and proceed to follow up. Patients with detectable MRD and an objective response to therapy are re-randomized to arm 2B or arm 2C.

ARM 2B: Patients continue zanubrutinib PO BID sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for an additonal 12 cycles in the absence of disease progression or unacceptable toxicity.

ARM 2C: Patients discontinue therapy starting at cycle 15 day 28 and proceed to follow up.

Patients undergo CT scan, bone marrow aspiration and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 3 years then every 6 months until 10 years for study registration. Patients with progression or the start of non protocol CLL directed therapy are followed every 6 months for 10 years from registration.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • STEP 0: This bone marrow or peripheral blood submission to Adaptive is mandatory prior to registration/randomization for real-time identification of the clone needed for MRD testing. The bone marrow sample should be from the first aspiration (i.e., first pull). Aspirate needle should be redirected if needed to get first pull bone marrow aspirate. It should be obtained as soon after pre-registration as possible to confirm registration eligibility
  • STEP 0: Patients must be diagnosed with CLL/SLL according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria that includes all of the following:

    • ≥ 5 x10\^9 /L B lymphocytes (5000/μL) in the peripheral blood (CLL) or a lymph node demonstrating SLL with the below immunophenotype (SLL)
    • On morphologic review, the leukemic cells must be small mature lymphocytes
    • Immunophenotype of CLL cells (performed locally) must reveal a clonal B-cell population, which coexpress the B cell surface markers of CD19 and CD20, as well as the T-cell antigen CD5. Patients with bright surface immunoglobulin expression or lack of CD23 expression in > 10% of cells must lack t(11;14) translocation by interphase cytogenetics
  • STEP 0: Patients must meet criteria for treatment as defined by IWCLL 2018 guidelines which includes at least one of the following criteria:

    • Evidence of marrow failure as manifested by the development or worsening of anemia or thrombocytopenia (not attributable to hemolytic anemia or thrombocytopenia), typically (Hb) \< 10 g/dL, count \< 100,000/mm\^3
    • Massive (> 6 cm below the costal margin), progressive or symptomatic splenomegaly
    • Massive nodes (ie, > 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy
    • Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy
    • Constitutional symptoms, which include any of the following:

      • Unintentional weight loss of ≥ 10% within the previous 6 months
      • Significant fatigue (ie. [ECOG] performance status [PS] ≥ 2)
      • Fevers >100.5 °F or 38.0°C for 2 weeks or more without evidence of infection
      • Night sweats > 1 month without evidence of infection
  • STEP 0: Patients must not have had prior therapy for CLL (except palliative or treatment of autoimmune complications of CLL with rituximab or steroids)
  • STEP 0: Treatment with rituximab and/or high-dose corticosteroids for autoimmune complications of CLL must be completed prior to enrollment. Palliative steroids must be at a dose not higher than 20 mg/day of prednisone or equivalent corticosteroid at the time of registration
  • STEP 0: Age ≥ 65 years
  • STEP 0: ECOG performance status ≤ 2
  • STEP 0: Patients with known infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
  • STEP 0: For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • STEP 0: Patients with a history of virus (HCV), infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • STEP 0: Patients must not be receiving active systemic anticoagulation with warfarin. Patients must be off warfarin therapy for at least 5 half-lives washout and with normal prior to enrollment
  • STEP 0: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients must be class 2B or better.

Patients with acute cardiac events within 6 months prior to registration should be carefully evaluated for their suitability for enrollment

  • STEP 0: No patients with a history of a severe bleeding disorder or a history of hemorrhagic stroke or intracranial hemorrhage
  • STEP 0: No patients with known active progressive central nervous system (CNS) disease
  • STEP 0: No known medical condition causing an inability to swallow oral formulations of agents
  • STEP 1: The adaptive report confirming a measurable and trackable B cell clone
  • STEP 1: Patients may not have had major surgery within 7 days of enrollment, or minor surgery within 5 days of enrollment. Examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint. The decision about whether a surgery is major or minor can be made at the discretion of the treating physician
  • STEP 1: No patients with ongoing active fungal, bacterial or viral infection requiring systemic therapy except those described in the protocol document
  • STEP 1: Patients must not require more than 20 mg prednisone or equivalent corticosteroid daily
  • STEP 1: Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics
  • STEP 1: Patients must not have continued requirement for therapy with a strong /5 inhibitor or inducer. Any such inhibitor or inducer must have been discontinued at least 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug
  • STEP 1: (ANC) ≥ 1,000/mm3 unless due to marrow involvement
  • STEP 1: Platelet count ≥ 30,000/mm3
  • STEP 1: Total ≤ 1.5 x (ULN) (unless due to liver involvement, hemolysis or Gilbert's disease)
  • STEP 1: (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 x upper limit of normal (ULN) unless due to disease infiltration of the liver
  • STEP 1: Calculated (calc.) by Chronic Kidney Disease Epidemiology Collaboration equation () ≥ 30 mL/min
  • STEP 1: Urine protein to creatinine ratio \< 1 or urine protein ≤ 1+
  • STEP 2: Detectable MRD ≥ 10 residual clonal cells per million nucleated cells in peripheral blood at the C15 restaging evaluation from ClonoSEQ
  • STEP 2: Response of PR, PR-L, CR, CCR or CRi to zanubrutinib sonrotoclax therapy
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
466 participants (estimated)

Study arms

  • Active comparator
    Arm 1 (zanubrutinib)

    Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with at least partial remission continue therapy as described above. Patients with progressive disease proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection throughout the study.

    Drug: Zanubrutinib · Procedure: Computed Tomography · Procedure: Bone Marrow Aspiration · Procedure: Biospecimen Collection · Other: Survey Administration

  • Experimental
    Arm 2 (zanubrutinib and sonrotoclax)

    Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Starting cycle 4 day 1 patients also receive sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with undetectable MRD and a response of PR, PR-L, CR, CCR or CRi stop therapy at cycle 15 day 28 and proceed to follow up. Patients with detectable MRD and an objective response to therapy are re-randomized to arm 2B or arm 2C. ARM 2B: Patients continue zanubrutinib PO BID sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for an additonal 12 cycles in the absence of disease progression or unacceptable toxicity. ARM 2C: Patients discontinue therapy starting at cycle 15 day 28 and proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection

    Drug: Zanubrutinib · Drug: Sonrotoclax · Procedure: Computed Tomography · Procedure: Bone Marrow Aspiration · Procedure: Biospecimen Collection · Other: Survey Administration

Interventions

  • Given PO

  • Given PO

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CT Scan, Cat Scan

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    From initial randomization date until the earlier of disease progression or death from any cause. PFS estimates for zanubrutinib plus sonrotoclax therapy to continuous Zanubrutinib.

    Time frame: From initial randomization date until the earlier of disease progression or death from any cause, up to 10 years

Other outcomes

  1. PFS for patients with MRD detectable disease treated with fixed duration zanubrutinib sonrotoclax versus patients with MRD detectable disease who receive one additional year of combination therapy

    Undetectable (u) MRD will be defined as \< 10 in 1,000,000 (less than 1 in 10\^-5 \[uMRD5\]) on peripheral blood, and the depth of response below that level, (i.e. down to 10\^-6 \[uMRD6\]), will also be collected. Kaplan-Meier will be used to estimate survival curves, log-rank tests to compare between survival curves, and hazard ration (HRs) and associated 95% CIs will be reported.

    Time frame: up to 10 years

  2. Overall survival

    OS will be summarized using Kaplan-Meier methodology, with hazard ratios from a stratified Cox proportional hazards model and log-rank test results provided.

    Time frame: Up to 10 years

  3. Percentage of patients with MRD detectable disease who convert to uMRD after receiving an extra year of combination therapy on the MRD-guided Zanubrutinib sonrotoclax therapy arm

    Proportions of number of MRD+ to uMRD conversion by total number of evaluable patients will be estimated with their corresponding 95% CIs.

    Time frame: Up to 10 years

  4. Overall response rate among treatment arms

    Overall response rate is defined as the highest response achieved during the first 15 cycles of treatment. A response is defined as a patients achieving PR+.

    Time frame: Up to 10 years

  5. Time to next CLL/SLL therapy

    Kaplan-Meier estimates and 95% CIs of TTNT. Time is measured as the time from the end of initial treatment to the initiation of subsequent treatment.

    Time frame: Up to 10 years

  6. Adverse Event Rates and Severity

    Frequency and severity of adverse events and tolerability for each embedded treatment regimen will be collected and summarized using descriptive statistics.

    Time frame: Up to 10 years

  7. Patient-reported symptomatic adverse events

    As assessed by the Patient Reported Outcome-Common Terminology Criteria for Adverse Events, the frequency and proportion of patients with a maximum baseline-adjusted composite score greater than 0 will be compared between arms using Fisher's exact test. Similarly, the frequency and proportion of patients with a maximum baseline-adjusted composite score greater than or equal to 3 will be compared between arms using Fisher's exact test.

    Time frame: Up to 10 years

07

Study locations

259 of 261 sites recruiting

Showing the first 100 of 261 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2028, 29 months after the start.

Of 83 phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 76. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 7, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2038
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
51 sites added. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
  • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
  • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
Show 51 added (51 United States)
  • Kaiser Permanente-Franklin · Denver, United States
  • Kaiser Permanente-Rock Creek · Lafayette, United States
  • Kaiser Permanente-Lone Tree · Lone Tree, United States
  • Glens Falls Hospital · Glens Falls, United States
  • Cleveland Clinic Akron General · Akron, United States
  • Avon - Richard E Jacobs Health Center · Avon, United States
  • Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland, United States
  • Cleveland Clinic Foundation · Cleveland, United States
  • Hillcrest Hospital Cancer Center · Mayfield Heights, United States
  • Geisinger Medical Center · Danville, United States
  • Geisinger Wyoming Valley/Henry Cancer Center · Wilkes-Barre, United States
  • Rhode Island Hospital · Providence, United States
  • VCU Massey Comprehensive Cancer Center · Richmond, United States
  • VCU Health Tappahannock Hospital · Tappahannock, United States
  • Kaiser Permanente Dublin · Dublin, United States
  • Kaiser Permanente-Fremont · Fremont, United States
  • Kaiser Permanente Fresno Orchard Plaza · Fresno, United States
  • Kaiser Permanente- Modesto MOB II · Modesto, United States
  • Kaiser Permanente-Oakland · Oakland, United States
  • Kaiser Permanente-Roseville · Roseville, United States
  • Kaiser Permanente Downtown Commons · Sacramento, United States
  • Kaiser Permanente-South Sacramento · Sacramento, United States
  • Kaiser Permanente-San Francisco · San Francisco, United States
  • Kaiser Permanente-Santa Teresa-San Jose · San Jose, United States
  • Kaiser Permanente San Leandro · San Leandro, United States
  • Kaiser San Rafael-Gallinas · San Rafael, United States
  • Kaiser Permanente Medical Center - Santa Clara · Santa Clara, United States
  • Kaiser Permanente-Santa Rosa · Santa Rosa, United States
  • Kaiser Permanente-South San Francisco · South San Francisco, United States
  • Kaiser Permanente-Vallejo · Vallejo, United States
  • …and 21 more on the registry record
across 2 updates, Oct 2, 2026 – Nov 3, 2026
Site contacts
Changed at 9 sites. See the sites
Show 9 sites
  • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
  • Swedish Cancer Institute-Edmonds · Edmonds, United StatesContact added P•••@swedish.org · •••2343Contact added (no phone or email listed)
  • Swedish Medical Center-First Hill · Seattle, United StatesContact added P•••@swedish.org · •••2343Contact added (no phone or email listed)
  • ProHealth D N Greenwald Center · Mukwonago, United StatesContact added r•••@phci.orgContact added (no phone or email listed)
  • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesContact added •••7878Contact added (no phone or email listed)
  • UW Cancer Center at ProHealth Care · Waukesha, United StatesContact added C•••@phci.org · •••5539Contact added (no phone or email listed)
across 2 updates, Oct 2, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    37 sites added. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
    • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
    • Swedish Cancer Institute-Edmonds · Edmonds, United StatesSuspended→Recruiting
    • Swedish Medical Center-First Hill · Seattle, United StatesSuspended→Recruiting
    Show 37 added (37 United States)
    • Kaiser Permanente Dublin · Dublin, United States
    • Kaiser Permanente-Fremont · Fremont, United States
    • Kaiser Permanente Fresno Orchard Plaza · Fresno, United States
    • Kaiser Permanente- Modesto MOB II · Modesto, United States
    • Kaiser Permanente-Oakland · Oakland, United States
    • Kaiser Permanente-Roseville · Roseville, United States
    • Kaiser Permanente Downtown Commons · Sacramento, United States
    • Kaiser Permanente-South Sacramento · Sacramento, United States
    • Kaiser Permanente-San Francisco · San Francisco, United States
    • Kaiser Permanente-Santa Teresa-San Jose · San Jose, United States
    • Kaiser Permanente San Leandro · San Leandro, United States
    • Kaiser San Rafael-Gallinas · San Rafael, United States
    • Kaiser Permanente Medical Center - Santa Clara · Santa Clara, United States
    • Kaiser Permanente-Santa Rosa · Santa Rosa, United States
    • Kaiser Permanente-South San Francisco · South San Francisco, United States
    • Kaiser Permanente-Vallejo · Vallejo, United States
    • Kaiser Permanente-Walnut Creek · Walnut Creek, United States
    • UCHealth Memorial Hospital Central · Colorado Springs, United States
    • Memorial Hospital North · Colorado Springs, United States
    • Grand Valley Oncology · Grand Junction, United States
    • Kaiser Permanente Moanalua Medical Center · Honolulu, United States
    • UW Health Carbone Cancer Center Rockford · Rockford, United States
    • Ochsner LSU Health Monroe Medical Center · Monroe, United States
    • LSU Health Sciences Center at Shreveport · Shreveport, United States
    • Beth Israel Deaconess Medical Center · Boston, United States
    • Wayne State University/Karmanos Cancer Institute · Detroit, United States
    • Weisberg Cancer Treatment Center · Farmington Hills, United States
    • Minnesota Oncology - Burnsville · Burnsville, United States
    • Minnesota Oncology - Edina · Edina, United States
    • Mayo Clinic in Rochester · Rochester, United States
    • …and 7 more on the registry record
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Swedish Cancer Institute-Edmonds · Edmonds, United StatesContact added P•••@swedish.org · •••2343Contact added (no phone or email listed)
    • Swedish Medical Center-First Hill · Seattle, United StatesContact added P•••@swedish.org · •••2343Contact added (no phone or email listed)
    + 1 other change: verification date
  2. Oct 2, 2026
    14 sites added. 7 sites changed recruiting status (4 now suspended, 3 now recruiting)
    Show 7 sites
    • Providence Newberg Medical Center · Newberg, United StatesRecruiting→Suspended
    • Providence Willamette Falls Medical Center · Oregon City, United StatesRecruiting→Suspended
    • Swedish Cancer Institute-Edmonds · Edmonds, United StatesRecruiting→Suspended
    • Swedish Medical Center-First Hill · Seattle, United StatesRecruiting→Suspended
    • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
    • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
    • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
    Show 14 added (14 United States)
    • Kaiser Permanente-Franklin · Denver, United States
    • Kaiser Permanente-Rock Creek · Lafayette, United States
    • Kaiser Permanente-Lone Tree · Lone Tree, United States
    • Glens Falls Hospital · Glens Falls, United States
    • Cleveland Clinic Akron General · Akron, United States
    • Avon - Richard E Jacobs Health Center · Avon, United States
    • Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland, United States
    • Cleveland Clinic Foundation · Cleveland, United States
    • Hillcrest Hospital Cancer Center · Mayfield Heights, United States
    • Geisinger Medical Center · Danville, United States
    • Geisinger Wyoming Valley/Henry Cancer Center · Wilkes-Barre, United States
    • Rhode Island Hospital · Providence, United States
    • VCU Massey Comprehensive Cancer Center · Richmond, United States
    • VCU Health Tappahannock Hospital · Tappahannock, United States
    Site contacts Changed at 9 sites. See the sites
    Show 9 sites
    • Providence Newberg Medical Center · Newberg, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • Swedish Cancer Institute-Edmonds · Edmonds, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
    • Swedish Medical Center-First Hill · Seattle, United StatesContact removed P•••@swedish.org · •••2343Contact removed (no phone or email listed)
    • ProHealth D N Greenwald Center · Mukwonago, United StatesContact added r•••@phci.orgContact added (no phone or email listed)
    • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesContact added •••7878Contact added (no phone or email listed)
    • UW Cancer Center at ProHealth Care · Waukesha, United StatesContact added C•••@phci.org · •••5539Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07321652
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Apr 30, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2038 (estimated)
Last update
Nov 3, 2026

Study contacts

Jayke Giese
Contact
leukemiaprotocols@alliancenctn.org
773-702-9171
Jennifer R Brown, MD
study chair · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion